Skip to Content

Lyrica Approval History

Lyrica (pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury; as an adjunctive therapy for partial onset seizures and for the treatment of fibromyalgia.

Development History and FDA Approval Process for Lyrica

Oct 12, 2017Approval FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions
Jun 21, 2012Approval FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review
Jun 22, 2007Approval FDA Approves First Drug for Treating Fibromyalgia - Lyrica
Dec 31, 2004Approval Lyrica Pfizer Inc. - Treatment for Neuropathic Pain
Sep  2, 2004Pfizer Statement on Regulatory Status of Lyrica

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.